RxDoctor Payments Data

Ashwin Gupta

Physician Assistant · Philadelphia, PANPI 1033766480

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 87.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $28,407, more than ten times the $1,449 reported in 2021. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,819in general payments, 2019–2025

Across 121 payments — averaging $271.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$29K
  • AbbVie$975
  • Novo Nordisk$790
  • Viiv Healthcare Company$490
  • GSK$466
  • AstraZeneca$372
  • plus $929 from 9 others

What the payments were for

  • Consulting fees$4,98015%
  • Speaking & faculty fees$15,00846%
  • Travel & lodging$6,96121%
  • Food & beverage$5,87118%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,819 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala67$265,378
CabenuvaCabotegravir/Rilpivirine15$100,348
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$67,306
JulucaDolutegravir/Rilpivirine11$35,863
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$28,798$265,37867 claims
Viiv Healthcare CompanyCabenuva, Juluca$490$136,21226 claims
Janssen Products, LPSymtuza$74$67,30615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →